Brief Title
A Prospective Study of Fractional Flow Reserve Assessment of Intermediate Coronary Stenoses in Severe Aortic Stenosis
Official Title
A Prospective Study of Fractional Flow Reserve Assessment of Intermediate Coronary Stenoses in Severe Aortic Stenosis
Brief Summary
Coronary artery blockages can reduce blood flow to the heart muscle. Fractional flow reserve (iFR or FFR) assessment is an invasive tool used to determine how much blood flow is reduced. The investigators will perform iFR/FFR on all intermediate coronary stenoses using standard practice, immediately before (at the time of) transcatheter aortic valve replacement (TAVR) and after successful TAVR. The investigators will compare pre- and post-TAVR iFR/FFR values, and assess short-term outcomes. The investigators hypothesize that iFR/FFR values will be consistently and significantly higher pre-TAVR in comparison with post-TAVR for the same lesions.
Detailed Description
The purpose of the study is to determine whether iFR assessment gives a valid assessment of coronary hemodynamics in patients with severe aortic stenosis. Several factors confound the interpretation of fractional flow reserve (FFR) in patients with severe aortic stenosis (AS) and intermediate severity coronary stenoses, and the widely accepted cut-off value of 0.80 may not be applicable to this patient population. Coronary flow reserve is known to be attenuated under conditions of left ventricular hypertrophy and severe AS, with one study showing improvement in coronary flow reserve after aortic valve replacement. Left ventricular hypertrophy produces fixed resistance secondary to external compression of the coronary microcirculation. This potentially results in failure to achieve maximal hyperemia with adenosine and can lead to false negative FFR results. Neurohormonal influences in aortic stenosis can further attenuate vasodilator response and potentially result in false negative FFR values. Both of these conditions result in the potential deferral of lesions which may have been hemodynamically significant in the absence of severe AS. At present, there are no studies which have demonstrated validity of FFR measurement in patients with severe AS. Here, the investigators propose a prospective study of iFR/FFR in patients with AS and indeterminate coronary lesions undergoing TAVR to understand the hemodynamic consequences of AS on iFR/FFR. The investigators hypothesize that iFR/FFR values will be consistently and significantly higher pre-TAVR in comparison with post-TAVR for the same lesions.
Study Type
Interventional
Primary Outcome
iFR/FFR
Condition
Coronary Artery Stenoses
Intervention
Volcano iFR/FFR Verrata Plus coronary pressure/flow wire
Study Arms / Comparison Groups
FFR/iFR arm
Description: Volcano iFR/FFR Verrata Plus coronary pressure/flow wire
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Device
Estimated Enrollment
5
Start Date
February 14, 2018
Completion Date
August 10, 2021
Primary Completion Date
August 10, 2021
Eligibility Criteria
Inclusion Criteria: - All patients who have coronary stenoses between 40-70% severity and who have severe aortic stenosis undergoing TAVR work-up. Exclusion Criteria: - Patients with documented intraprocedural hemodynamic instability, shock, or major adverse event (myocardial infarction, aortic rupture/dissection, stroke, left ventricular perforation, cardiac arrest). - Contraindication to adenosine, presence of cardiogenic shock, presence of acute coronary syndrome.
Gender
All
Ages
20 Years - 110 Years
Accepts Healthy Volunteers
No
Contacts
Samir R Kapadia, MD, ,
Location Countries
United States
Location Countries
United States
Administrative Informations
NCT ID
NCT03442400
Organization ID
IRB 17-695
Responsible Party
Principal Investigator
Study Sponsor
The Cleveland Clinic
Collaborators
Volcano Corporation
Study Sponsor
Samir R Kapadia, MD, Principal Investigator, The Cleveland Clinic
Verification Date
September 2021